Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 1Neoplasms by Histologic Type 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Gemcitabine 3pembrolizumab 2napabucasin 2entinostat 2Taxes 2Sunitinib 2Sorafenib 2130-nm albumin-bound paclitaxel 2trametinib 1siltuximab 1repotrectinib 1pralsetinib 1lutetium Lu 177 dotatate 1linifanib 1durvalumab 1dabrafenib 1copper dotatate CU-64 1cobimetinib 1capmatinib 1atezolizumab 1Vemurafenib 1Pemetrexed 1Paclitaxel 1Lutetium-177 1Lutetium 1Leucovorin 1Irinotecan 1Immunotherapy 1HhAntag691 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × siltuximab × Gastrointestinal × Clear all
NCT00841191 2014-05-14

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Centocor, Inc.

Phase 1/2 Completed
84 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms by Histologic Type, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡